Andrew Horine, DO
Family Medicine · Carrollton, MONPI 1720342629
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,163 of the $19,498 with a category attached, or 72.6%. Mimedx Group, Inc. accounts for 80.7% of it on its own, with 42 other manufacturers making up the rest. 2025 is the largest year on record at $11,542, more than ten times the $369 reported in 2019. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $80.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$16K
- AbbVie$881
- Lilly USA, LLC$343
- AstraZeneca$281
- Lundbeck LLC$179
- Boehringer Ingelheim$169
- plus $2K from 37 others
What the payments were for
- Speaking & faculty fees$14,16373%
- Travel & lodging$8995%
- Food & beverage$4,43623%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOVINE COLLAGEN$2,411
How this compares
$19,498 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $123,192 |
| JardianceEmpagliflozin | 106 | $84,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $39,642 |
| EliquisApixaban | 58 | $37,575 |
| TrulicityDulaglutide | 30 | $34,824 |
| VraylarCariprazine Hcl | 22 | $31,521 |
| MounjaroTirzepatide | 26 | $27,955 |
| MyrbetriqMirabegron | 54 | $27,487 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 57 | $27,166 |
| LinzessLinaclotide | 44 | $23,470 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $20,196 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $20,070 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $15,875 |
| XareltoRivaroxaban | 14 | $14,702 |
| JanuviaSitagliptin Phosphate | 16 | $13,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $105 | $123,192126 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $169 | $111,576163 claims |
| AbbVieVraylar, Linzess, Restasis Multidose, Restasis | $881 | $70,68091 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Arexvy | $29 | $66,881129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $343 | $62,77956 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Brilinta | $281 | $47,873111 claims |
| PfizerEliquis, Abrysvo | $138 | $42,19273 claims |
| MerckJanuvia, Janumet Xr, Janumet | $102 | $30,71753 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $27,48754 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $49 | $16,24328 claims |
| Johnson & JohnsonXarelto | $56 | $14,70214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Carrollton
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.